Subtopic Deep Dive
Progressive Multifocal Leukoencephalopathy
Research Guide
What is Progressive Multifocal Leukoencephalopathy?
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by JC polyomavirus reactivation in immunocompromised individuals.
PML manifests with progressive neurological deficits due to JC virus infection of oligodendrocytes, leading to multifocal demyelination. Studies emphasize risk factors including natalizumab, rituximab, and HIV immunosuppression. Over 10 key papers from 2005-2015 document associations with monoclonal antibody therapies, with Bloomgren et al. (2012) cited 1214 times.
Why It Matters
PML risk stratification guides safer use of biologics like natalizumab in multiple sclerosis and Crohn's disease patients (Bloomgren et al., 2012; Van Assche et al., 2005). Rituximab-related PML cases in HIV-negative patients highlight monitoring needs for lymphoproliferative and autoimmune treatments (Carson et al., 2009). Diagnostic criteria and anti-JC virus serology enable early intervention, reducing mortality in immunosuppressed populations (Berger et al., 2013; Gorelik et al., 2010).
Key Research Challenges
Risk Stratification Accuracy
Identifying PML risk from anti-JC virus antibodies, treatment duration, and prior immunosuppressants remains imprecise despite models (Bloomgren et al., 2012). Antibody index levels refine but do not eliminate uncertainty in natalizumab users (Plavina et al., 2014). Combining factors yields distinct risk levels yet requires validation across populations.
Diagnostic Confirmation
Definitive PML diagnosis demands histopathologic triad and JC virus detection, challenging in living patients (Berger et al., 2013). MRI guidelines aid but overlap with MS lesions (MAGNIMS study group, 2015). Non-invasive biomarkers lag behind.
Antiviral Treatment Lack
No effective antivirals exist for JC virus; immune reconstitution is primary strategy (Tan and Koralnik, 2010). Natalizumab cessation risks immune rebound encephalitis. Therapy development hindered by virus latency in healthy hosts (Egli et al., 2009).
Essential Papers
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren, Sandra Richman, Christophe Hotermans et al. · 2012 · New England Journal of Medicine · 1.2K citations
Positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct le...
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
Bette K. Kleinschmidt‐DeMasters, Kenneth L. Tyler · 2005 · New England Journal of Medicine · 1.1K citations
A 46-year-old woman with relapsing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after having received 37 doses of natalizumab (300 mg every four weeks) as...
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Gert Van Assche, Marc Van Ranst, Raf Sciot et al. · 2005 · New England Journal of Medicine · 1.1K citations
The prior diagnosis of fatal astrocytoma in a 60-year-old man with Crohn's disease treated with natalizumab, a monoclonal antibody against alpha4 integrins, was reclassified as JC virus-related pro...
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson, Andrew M. Evens, Elizabeth Richey et al. · 2009 · Blood · 865 citations
Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients with systemic lupus erythe...
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
Chen Sabrina Tan, Igor J. Koralnik · 2010 · The Lancet Neurology · 769 citations
Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
Adrian Egli, Laura Infanti, Alexis Dumoulin et al. · 2009 · The Journal of Infectious Diseases · 767 citations
Our study provides important data about polyomavirus infection and replication in healthy, immunocompetent individuals. These data indicate significant differences between BKV and JCV with respect ...
PML diagnostic criteria
Joseph R. Berger, Allen J. Aksamit, David B. Clifford et al. · 2013 · Neurology · 678 citations
Definitive diagnosis of PML requires neuropathologic demonstration of the typical histopathologic triad (demyelination, bizarre astrocytes, and enlarged oligodendroglial nuclei) coupled with the te...
Reading Guide
Foundational Papers
Start with Bloomgren et al. (2012) for natalizumab risk model (1214 citations), Kleinschmidt-DeMasters (2005) and Van Assche (2005) for first cases in MS and Crohn's, then Tan and Koralnik (2010) for pathogenesis.
Recent Advances
Plavina et al. (2014) refines antibody index risks; Berger et al. (2013) sets diagnostic criteria; MAGNIMS (2015) updates MRI protocols.
Core Methods
Anti-JC virus ELISA for serology (Gorelik et al., 2010); CSF JC PCR and brain biopsy; MRI T2/FLAIR lesions with restricted diffusion.
How PapersFlow Helps You Research Progressive Multifocal Leukoencephalopathy
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve natalizumab-PML risk papers like Bloomgren et al. (2012), then citationGraph maps connections to Plavina et al. (2014) and findSimilarPapers uncovers rituximab cases (Carson et al., 2009).
Analyze & Verify
Analysis Agent applies readPaperContent to Bloomgren et al. (2012) abstracts for risk factor extraction, verifyResponse with CoVe checks seroprevalence claims against Egli et al. (2009), and runPythonAnalysis computes citation-normalized risk ratios with GRADE grading for evidence strength in diagnostics (Berger et al., 2013).
Synthesize & Write
Synthesis Agent detects gaps in antiviral therapies from Tan and Koralnik (2010), flags contradictions in natalizumab risk across Kleinschmidt-DeMasters (2005) and Van Assche (2005); Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10+ papers, and exportMermaid for PML pathogenesis flowcharts.
Use Cases
"Analyze JC virus seroprevalence trends in natalizumab patients from key papers."
Research Agent → searchPapers('JC virus natalizumab') → Analysis Agent → runPythonAnalysis(pandas on prevalence data from Bloomgren 2012, Plavina 2014) → CSV export of risk trends.
"Draft LaTeX review on PML diagnostics citing Berger 2013 and MAGNIMS 2015."
Synthesis Agent → gap detection → Writing Agent → latexEditText(structured sections) → latexSyncCitations(8 papers) → latexCompile(PDF) with MRI guideline figure.
"Find code for JC virus genome analysis in PML papers."
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect(viral sequencing pipelines linked to Egli 2009).
Automated Workflows
Deep Research workflow scans 50+ PML papers via searchPapers, structures reports on risk factors with GRADE scoring (Bloomgren et al., 2012). DeepScan applies 7-step CoVe verification to natalizumab case reports (Kleinschmidt-DeMasters, 2005). Theorizer generates hypotheses on antibody index thresholds from Plavina et al. (2014).
Frequently Asked Questions
What defines PML?
PML is JC virus-induced demyelination in immunocompromised patients, confirmed by histopathology showing demyelination, bizarre astrocytes, enlarged oligodendroglial nuclei, and JC virus (Berger et al., 2013).
What are main diagnostic methods?
Diagnosis uses MRI for asymmetric white matter lesions, PCR for JC virus in CSF, and biopsy for definitive triad; MAGNIMS guidelines distinguish from MS (MAGNIMS study group, 2015; Berger et al., 2013).
What are key papers?
Bloomgren et al. (2012, 1214 citations) stratifies natalizumab PML risk; Kleinschmidt-DeMasters (2005, 1068 citations) reports first MS case; Carson et al. (2009, 865 citations) details 57 rituximab cases.
What open problems exist?
Challenges include antiviral development, precise risk models beyond antibodies and duration (Plavina et al., 2014), and non-invasive diagnostics replacing biopsy (Tan and Koralnik, 2010).
Research Polyomavirus and related diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Progressive Multifocal Leukoencephalopathy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Polyomavirus and related diseases Research Guide